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Abstract
Background: Giant cell tumor of bone (GCT) is a rare primary bone tumor, which can metastasize and undergo
malignant transformation. The standard treatment of GCT is surgery. In patients with unresectable or metastatic
disease, additional therapeutic options are available. These include blocking of the receptor activator of NF-kappa B
ligand (RANKL) signaling pathway, which plays a role in the pathogenesis of GCT of bone, via the anti-RANKL
monoclonal antibody denosumab.
Case Presentation: Herein we report on a female teenager who presented in a very poor clinical condition
(cachexia, diplopia, strabismus, dysphonia with palsy of cranial nerves V, VI, VIII, IX, X, XI and XII) due to progressive
disease, after incomplete resection and adjuvant radiotherapy, of a GCT which affected the cervical spine (C1 and
C2) as well as the skull base; and who had an impressive clinical response to denosumab therapy. To the best of
our knowledge, this is the youngest patient ever reported with a skull base tumor treated with denosumab.
Conclusion: In situations when surgery can be postponed and local aggressiveness of the tumor does not urge for
acute surgical intervention, upfront use of denosumab in order to reduce the tumor size might be considered.
Principally, the goal of denosumab therapy is to reduce tumor size as much as possible, with the ultimate goal to
make local surgery (or as in our case re-surgery) amenable. However, improvement in quality of life, as
demonstrated in our patient, is also an important aspect of such targeted therapies.
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Background
Giant cell tumor of bone (GCT) is a rare neoplasm and
accounts for about 3–5% of primary bone tumors [1].
Although classified as benign, GCTs can grow locally ag-
gressive with a high rate of local recurrence (up to 60%)
when treated only by intralesional curettage. GCTs also
rarely metastasize to the lungs (5%) and may undergo
malignant transformation to high grade osteosarcoma in
1–3% of patients [2].
These neoplasms usually occur in young adults (aged
20–40 years) [3–5], and typically involve the epip-
hysiometaphyseal region of long bones (e.g., the knee
region) [6]. Less than 1% of all GCTs are found in the
skull (mostly arising from sphenoid or temporal bones)
[7–10] and the largest series of patients with affection of
the cervical spine encompassed only 22 patients [11].
The standard treatment of GCT is near complete re-
moval of tumor with polymethylmethacrylate adjuvants
avoiding mutilations [12]. GCTs at axial sites are more
difficult to treat, with a higher rate of local recurrence;
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and skull and spine sites are sometimes deemed inoper-
able, because of the proximity to vital structures like
major cerebral vessels [7, 11, 13]. In GCT of the skull
and spine surgical debulking with adjuvant radiotherapy
is a therapeutic option [14, 15].
Additional adjuvant therapeutic options are available
for the use in patients with unresectable or metastatic
disease; and include blocking of the receptor activator of
NF-kappa B ligand (RANKL) signaling pathway, which
plays a role in the pathogenesis of GCT of bone, via the
anti-RANKL monoclonal antibody denosumab. GCTs
histologically consist of three cell types: multinuclear
osteoclast like giant cells, neoplastic stromal cells, repre-
senting the proliferative fraction and CD68 positive
mononuclear histocytic cells. Neoplastic stromal cells
produce receptor activator of nuclear factor kappa-B lig-
and (RANKL) and induce multinuclear osteoclast like
giant cell precursors which express receptor activator of
nuclear factor kappa-B (RANK). Denosumab blocks the
RANKL-RANK interaction between stromal cells and
osteoclastic giant cell precursors inhibiting their matur-
ation and as result bone resorption. Moreover, denosu-
mab also reduces the relative content of proliferative
tumor stromal cells and also has an anti-angiogenic ef-
fect [3, 16–20].
Herein, we report on a female teenager who, after sev-
eral lines of unsuccessful therapeutic approaches, had an
impressive clinical response to denosumab therapy. This
is the youngest patient ever reported with a skull base
tumor treated with denosumab.
Case Presentation
A 14 year-old Caucasian female complained of head-
aches and neck pain for 8 months. These symptoms be-
came more severe and additionally difficulty with
swallowing and discoordination occurred. Computed
tomography (CT) and magnetic resonance imaging
(MRI) were performed and demonstrated an irregularly
shaped, inhomogeneous intra-extracranial pathologic
formation in the craniovertebral region, which seemed
to arise from the C2 vertebrae, mainly at the left, with
anteroposterior size up to 4.4 cm, a transverse size up to
5.5 cm and a cranio-caudal size up to 5.2 cm. The tumor
comprised the craniovertebral transition, decayed the
bone structure of the atlanto-occipital and atlanto-axial
joints (causing luxation of atlanto-occipital articulation),
as well as the upper third of the processus odontoideus
of C2. It penetrated into the spinal canal, narrowed the
foramen magnum, compressed the medulla oblongata
and the upper sections of the cervical spinal cord, and
constricted the foramen of Magendie without impair-
ment of liquorodynamics. The C2 vertebral body was
fully comprised in the process and rotated around its
axis. The tumor invaded into the body of the sphenoid
bone and reached almost to the level of the pons. An-
teriorly, it reached the nasopharyngeal region without
entering the nasopharyngeal space. Immediately poster-
ior to the tumor the arteria basilaris was passing, with
no evidence of its invasion. The left vertebral artery was
lost in the thickness of the tumor. Left internal carotid
artery and left jugular vein abutted to the left margin of
the pathologic mass. The tumor also compressed the left
cerebellar hemisphere displacing it backwards and to the
top. (Additional file 1: Figure S1).
Posterior craniocervical decompression was performed
with occipitospondylodesis and endonasal biopsy of the
C2 vertebral body. Histological and immunohistochemi-
cal examinations showed giant cell tumor of bone with
local aggressive growth (CD68+, CD99+, BCL2+, Actin+,
D2-40+, Ki67 5%).
Subsequently, she was referred to Moscow, where
around 2.5 months later incomplete surgical resection
was performed. It was reported, that after initial
tracheostomy endoscopic transnasal and microsurgical
transoral subtotal removal of tumor was performed.
Preoperative neurological pathology included severe
craniocervical pain, grade 3–4 dysphagia, hoarseness,
hypesthesia of the 2nd branch of the 5th cranial
nerve, and deviation of the tongue to the left. These
symptoms improved partially after surgery (relieve of
craniocervical pain; partial regression of symptoms of
bulbar violation together with failure of 2nd branch
of the 5th cranial nerve). It was reported that post-
surgical CT revealed residual tumor mass at the skull
base mostly at the left.
After recovering from surgery she returned back to
Armenia. Since then her preoperative symptoms grad-
ually recurred. She received 3D conformal external beam
radiotherapy (EBRT) using four coplanar fields to deliver
total dose of 50.4Gy in 28 fractions. During and after
completion of EBRT the above-mentioned symptoms
didn’t get milder, and her health condition deteriorated.
MRI performed after the EBRT (3 months after sur-
gery) showed progressive growth of tumor reaching
5,7 × 7,1 × 6,0 cm (Additional file 1: Figure S2).
Four weeks after completion of radiotherapy, the pa-
tient presented to our clinic with severe cachexia, cra-
niocervical pain, discoordination, swallowing problems
(grade 3–4 dysphagia), taste loss, diplopia, left eye stra-
bismus, left auricular pain with partial deafness and dys-
phonia. She couldn’t stick out the tongue, which was
deviated to the left, had difficulties with raising shoul-
ders and was almost unable to turn the head to the right.
Neurological examination showed that cranial V, VI,
VIII, IX, X, XI and XII nerves were affected.
Due to the tumor size, location and its closeness to
vital structures a re-resection was considered impossible.
The patient’s health condition was extremely poor and
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continued to worsen; therefore the treatment had to be
started immediately.
The fact that several reports stated the significant effi-
ciency of denosumab, as well as good tolerability of this
therapy prompted us to implement therapy with denosu-
mab s/c 120 mg q4w with loading doses on days 8 and
15 of cycle 1 [3, 16, 17, 21].
Simultaneously she started taking 4000 IU oral vitamin
D per day (initially her vitamin D level was 10 μg/l) and
1000 mg oral calcium.
After the first infusion of denosumab, the clinical con-
dition improved significantly, and further neurological
improvements were observed with every injection of
denosumab. After two injections of the drug the patient
started eating and walking, taste sense partially recov-
ered, the hearing resumed, the diplopia disappeared, and
she was free of pain without pain medication. Subse-
quently she gained weight and after three injections of
denosumab she was discharged. After four cycles of
denosumab treatment a MRI was performed and con-
firmed tumor regression 3,2 × 6,8 × 5,2 cm (Additional
file 1: Figure S3), which was suspected from the delect-
able clinical course. Unfortunately, CT imaging before
and after denosumab therapy is not available; and bone
formation around the tumor cannot be assessed.
The patient is tolerating the denosumab treatment
very well without any severe adverse effects (lowest Ca2+
level was 0.91 mmol/l; normal range: 1.12 to 1.32 mmol/
l). She performs daily activities without any difficulties
and returned to school. At last presentation the swallow-
ing problems are almost eliminated (dysphagia grade 1),
strabismus disappeared, her voice has partially recov-
ered, and she has no difficulties with shrugging. How-
ever, some problems with turning the head to right
remain. The tongue can be sticked out only slightly, and
it is still deviated to the left.
Discussion
Giant cell tumor of bone most often occurs in young
adults and involves the epiphysiometaphyseal region
of long bones [3–6]. Only a minority of patients
present with tumors in axial sites [7–11], and such
manifestations are exceptionally rare in pediatric pa-
tients. To the best of our knowledge only 16 (includ-
ing our case) pediatric patients (aged between
7 weeks and 17 years) with GCTs of the cervical
spine (Table 1) and 20 children and adolescents with
GCTs of the skull base (Table 2) have been reported
[11, 22–35]. Most of them were treated with surgery
and/or radiotherapy. One patient was reported to
have been treated with chemotherapy (Table 1). Many
of these patients were treated in the pre-RANKL in-
hibitors era (i.e., in the last century).
The first and the only report describing beneficial ef-
fects of denosumab in the treatment of the skull base
GCT was published recently by Inoue and colleagues,
describing a 16 years-old male with a relapsed GCT of
the skull base treated with denosumab after failure of
the surgery, resulting in marked reduction in tumor size
[36].
To the best of our knowledge, our patient is the youn-
gest patient ever reported with a large progressive GCT
affecting the skull base and cervical spine, who
responded well to therapy with denosumab.
As in most patients with spine and skull base GCTs,
total surgical excision (which is the standard therapy for
GCT) was not feasible in our patient. After subtotal ex-
cision she therefore received RT. As neurological symp-
toms recurred gradually after surgery and became worse
during and after RT, and correlated with rapid tumor
growth (documented via MRI), we considered these
symptoms mainly caused by tumor growth and con-
cluded that RT, unfortunately, was not effective. There-
fore we decided to implement palliative treatment with
denosumab [3, 16, 17, 21]. Initial cycles of treatment,
however, showed excellent improvement in performance
status; and MRI performed after 4th treatment cycles
confirmed tumor regression. Radiotherapy can induce
malignant transformation in GCTs. However, it is un-
likely that this occurred in our patient, because the
tumor has grown already before start of radiotherapy,
the time-lag between radiotherapy and occurrence of
malignancy is considered to take longer [15], and there
was an excellent response to denosumab therapy. As
complete surgical remission is crucial for long-term sur-
vival in patients with GCTs, the long-term prognosis in
our patient is expected to be unfavorable. However, as
she is tolerating the denosumab therapy without any se-
vere adverse effects, we will continue denosumab
therapy.
Conclusion
Based on the experience in our patient and other similar
reports [3, 16–19, 36] where denosumab was effective in
reducing GCT size and brought to elimination of 90% or
more giant cells we would now use denosumab upfront
in order to reduce tumor size in similar situations. How-
ever, such an approach is only feasible, if surgery can be
postponed and local aggressiveness of the tumor does
not urge for acute surgical intervention.
Principally, the goal of denosumab therapy is to reduce
tumor size as much as possible, with the ultimate goal
to make local surgery (or as in our case re-surgery)
amenable. However, improvement in quality of life, as
demonstrated in our patient, is also an important aspect
of such targeted therapies.
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Additional file
Additional file 1: Figure S1. MRI at diagnosis. (A) axial, (B) coronal and
(C) sagittal section of T1 weighted MRI after contrast administration
revealing an intra-extracranial pathologic formation of craniovertebral re-
gion 4,4×5,5×5,2 cm in size, which was rapidly enhancing after the gado-
linium injection, with decay of bones of craniovertebral region, upper
third of processus odontoideus of C2 vertebrae, luxation of cervical verte-
brae at the level of atlantoaxial articulation, more profoundly on the right
side. Formation grows into the sphenoid bone reaching the brainstem,
largely the pons, constrictes foramen of Magendie, compresses the left
cerebellar hemisphere and reaches the nasopharyngeal region without
entering nasopharyngeal space. Figure S2. MRI after radiotherapy. (A)
axial, (B) coronal and (C) sagittal images of T1 weighted MRI after contrast
admision performed after surgery and radiation therapy revealed recur-
rence of the pathologic mass of the craniovertebral junction, up to
5,7×7,1×6,0 cm in size, with central necrosiss. Signs of decay, which re-
places clivus, ventral parts of C1-C2, and condyles of temporal bone. Ven-
trally it infiltrates retropharyngeal space, dorsally deformates and
obliterates lumen of pontine cistern and cisterna magna, compressing
ventral parts of brainstem. Figure S3. MRI after 4 cycles of denosumab.
(A) axial, (B) coronal and (C) sagittal images of T1 weighted MRI after con-
trast administration with image subtraction (C) after 4 cycles of denosu-
mab treatment revealing an intra-extracranial pathologic formation of
craniovertebral region 3,2×6,8×5,2 cm in size, with decay of bones of
atlantooccipital and atlantoaxial articulation and upper third of processus
odontoideus of C2 vertebrae, with spine offset to the right. The patho-
logical mass enhances after the gadolinium injection, with small hypoin-
tense areas, with indicate focal necrosis. The mass grows into the
sphenoid bone reaching the brainstem, largely the pons, ventrally
reaches nasopharyngeal region without entering nasopharyngeal space.
Dorsolateral parts of formation reach condyles of temporal bone, con-
stricts craniovertebral transition and deformates front loop of medulla.
The formation is inhomogen due to small parts of cystic transformation.
(DOCX 688 kb)
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